It’s Friday, the sun has been shining, cherry trees are blossoming, and it’s been a sensible 15 degrees Celsius outside.
And yet, most people of a working age have probably spent the day in front of computer screens, trying to meet imposing deadlines, getting things in order before the weekend can properly begin.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.